These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
271 related articles for article (PubMed ID: 24879340)
1. Identification of two poorly prognosed ovarian carcinoma subtypes associated with CHEK2 germ-line mutation and non-CHEK2 somatic mutation gene signatures. Ow GS; Ivshina AV; Fuentes G; Kuznetsov VA Cell Cycle; 2014; 13(14):2262-80. PubMed ID: 24879340 [TBL] [Abstract][Full Text] [Related]
2. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients. Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906 [TBL] [Abstract][Full Text] [Related]
3. Novel Axl-driven signaling pathway and molecular signature characterize high-grade ovarian cancer patients with poor clinical outcome. Rea K; Pinciroli P; Sensi M; Alciato F; Bisaro B; Lozneanu L; Raspagliesi F; Centritto F; Cabodi S; Defilippi P; Avanzi GC; Canevari S; Tomassetti A Oncotarget; 2015 Oct; 6(31):30859-75. PubMed ID: 26356564 [TBL] [Abstract][Full Text] [Related]
4. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals. Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067 [TBL] [Abstract][Full Text] [Related]
5. Association of Somatic Mutations of ADAMTS Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma. Liu Y; Yasukawa M; Chen K; Hu L; Broaddus RR; Ding L; Mardis ER; Spellman P; Levine DA; Mills GB; Shmulevich I; Sood AK; Zhang W JAMA Oncol; 2015 Jul; 1(4):486-94. PubMed ID: 26181259 [TBL] [Abstract][Full Text] [Related]
6. Germline and somatic mutations in homologous recombination genes among Chinese ovarian cancer patients detected using next-generation sequencing. Zhao Q; Yang J; Li L; Cao D; Yu M; Shen K; J Gynecol Oncol; 2017 Jul; 28(4):e39. PubMed ID: 28541631 [TBL] [Abstract][Full Text] [Related]
7. miRNA-200a/c as potential biomarker in epithelial ovarian cancer (EOC): evidence based on miRNA meta-signature and clinical investigations. Teng Y; Su X; Zhang X; Zhang Y; Li C; Niu W; Liu C; Qu K Oncotarget; 2016 Dec; 7(49):81621-81633. PubMed ID: 27835595 [TBL] [Abstract][Full Text] [Related]
8. Detection of Germline Mutations in Patients with Epithelial Ovarian Cancer Using Multi-gene Panels: Beyond BRCA1/2. Eoh KJ; Kim JE; Park HS; Lee ST; Park JS; Han JW; Lee JY; Kim S; Kim SW; Kim JH; Kim YT; Nam EJ Cancer Res Treat; 2018 Jul; 50(3):917-925. PubMed ID: 29020732 [TBL] [Abstract][Full Text] [Related]
9. Tumor mutation burden forecasts outcome in ovarian cancer with BRCA1 or BRCA2 mutations. Birkbak NJ; Kochupurakkal B; Izarzugaza JM; Eklund AC; Li Y; Liu J; Szallasi Z; Matulonis UA; Richardson AL; Iglehart JD; Wang ZC PLoS One; 2013; 8(11):e80023. PubMed ID: 24265793 [TBL] [Abstract][Full Text] [Related]
11. A Cost-Effectiveness Evaluation of Germline BRCA1 and BRCA2 Testing in UK Women with Ovarian Cancer. Eccleston A; Bentley A; Dyer M; Strydom A; Vereecken W; George A; Rahman N Value Health; 2017 Apr; 20(4):567-576. PubMed ID: 28407998 [TBL] [Abstract][Full Text] [Related]
12. High-risk epithelial ovarian cancer patients for hereditary ovarian cancer. Chirasophon S; Manchana T; Teerapakpinyo C J Obstet Gynaecol Res; 2017 May; 43(5):929-934. PubMed ID: 28188963 [TBL] [Abstract][Full Text] [Related]
13. Germline mutations in cancer susceptibility genes in high grade serous ovarian cancer in Serbia. Krivokuca A; Boljevic I; Jovandic S; Magic Z; Mandic A; Tomasevic Z; Brankovic-Magic M J Hum Genet; 2019 Apr; 64(4):281-290. PubMed ID: 30651582 [TBL] [Abstract][Full Text] [Related]
14. BRCA1 and BRCA2 mutations in ovarian cancer patients from China: ethnic-related mutations in BRCA1 associated with an increased risk of ovarian cancer. Shi T; Wang P; Xie C; Yin S; Shi D; Wei C; Tang W; Jiang R; Cheng X; Wei Q; Wang Q; Zang R Int J Cancer; 2017 May; 140(9):2051-2059. PubMed ID: 28176296 [TBL] [Abstract][Full Text] [Related]
15. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type. Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232 [TBL] [Abstract][Full Text] [Related]
16. Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer. Ramus SJ; Song H; Dicks E; Tyrer JP; Rosenthal AN; Intermaggio MP; Fraser L; Gentry-Maharaj A; Hayward J; Philpott S; Anderson C; Edlund CK; Conti D; Harrington P; Barrowdale D; Bowtell DD; Alsop K; Mitchell G; ; Cicek MS; Cunningham JM; Fridley BL; Alsop J; Jimenez-Linan M; Poblete S; Lele S; Sucheston-Campbell L; Moysich KB; Sieh W; McGuire V; Lester J; Bogdanova N; Dürst M; Hillemanns P; ; Odunsi K; Whittemore AS; Karlan BY; Dörk T; Goode EL; Menon U; Jacobs IJ; Antoniou AC; Pharoah PD; Gayther SA J Natl Cancer Inst; 2015 Nov; 107(11):. PubMed ID: 26315354 [TBL] [Abstract][Full Text] [Related]